Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

This study has been completed.
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc. Identifier:
First received: February 14, 2014
Last updated: March 23, 2016
Last verified: March 2016
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

Condition Intervention
Metastatic Breast Cancer
Locally Recurrent Breast Cancer
Drug: Nab-paclitaxel
Drug: IG-001

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer

Resource links provided by NLM:

Further study details as provided by Sorrento Therapeutics, Inc.:

Primary Outcome Measures:
  • Maximum observed concentration of paclitaxel (Cmax) [ Time Frame: Predose: 30 min; During infusion: 30 min; Post-infusion: 5, 10, 15, 30, and 45 min, and 1, 1.5, 2, 4, 7, 10, 24, 30 and 48 or 72 hr ]
  • Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf) [ Time Frame: Predose: 30 min; During infusion: 30 min; Post-infusion: 5, 10, 15, 30, and 45 min, and 1, 1.5, 2, 4, 7, 10, 24, 30 and 48 or 72 hr ]

Enrollment: 111
Study Start Date: March 2014
Study Completion Date: July 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Reference Drug - Nab-paclitaxel
260 mg/m2 administered intravenously over 30 minutes on Day 1
Drug: Nab-paclitaxel
260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
Other Name: Paclitaxel albumin-bound particles for injectable suspension
Experimental: Test Drug - IG-001
260 mg/m2 administered intravenously over 30 minutes on Day 1
Drug: IG-001
260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
Other Names:
  • Paclitaxel polymeric micelles for injectable suspension
  • Genexol-PM
  • Cynviloq

Detailed Description:

This study is designed to compare the pharmacokinetics (PK) of IG-001 and nab-paclitaxel in patients with metastatic or locally recurrent breast cancer. Patients meeting the eligibility criteria will be randomized to determine which drug is administered first.

  • Patients randomized to Group 1 will receive a single dose of IG-001 (Period 1) followed 3 weeks later by a single dose of nab-paclitaxel (Period 2).
  • Patients randomized to Group 2 will receive a single dose of nab-paclitaxel (Period 1) followed 3 weeks later by a single dose of IG-001 (Period 2).

Blood samples for PK analysis will be taken at specified times before, during, and after the infusion of each drug in Periods 1 and 2. Following successful completion of Period 1 and Period 2, patients may be eligible for up to 4 additional cycles of treatment with IG-001 in the extension study.

Safety will be monitored throughout the study.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Breast cancer patient who

    1. Has histologically confirmed diagnosis of breast cancer.
    2. Has stage IV or locally recurrent breast cancer per the American Joint Committee on Cancer Staging Manual,7th edition.
    3. Has failed any single agent or combination chemotherapy for metastatic or locally recurrent disease.
    4. Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.
  2. Sex and Age: Female ≥ 30 years of age.
  3. Body surface area (BSA) that is within 1.2 to 2.2 m2, calculated using the Mosteller or DuBois Formula. The same formula must be used consistently for any given patient.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  5. Sitting blood pressure (BP) and heart rate (HR): Systolic and diastolic BP (SBP/DBP) and HR in the normal range or no worse than Grade 1 abnormality by the Common Terminology Criteria for Adverse Events version 4, as amended (CTCAE).
  6. Hematology/chemistry: Patient has adequate hematological, renal, and hepatic function as defined by the following Screening laboratory values obtained within 7 days prior to randomization and assessed based on local labs (patients should not have received a transfusion within 7 days before the Screening laboratory assessments):

    1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 (1.5x10^9/L)
    2. Platelet count ≥ 100,000 cells/mm3 (100x10^9/L)
    3. Hemoglobin ≥ 9 g/dL
    4. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)
    5. Total bilirubin ≤ 1.25 x ULN
    6. AST (SGOT) ≤ 2.5 x ULN
    7. ALT (SGPT) ≤ 2.5 x ULN
  7. All other clinical laboratory values deemed normal or not clinically significant by the Principal Investigator/Sub-Investigator.
  8. Pregnancy status: Patients must be non-pregnant (due to teratogenic or abortifacient effects of paclitaxel) from 30 days prior to randomization until 30 days after the last dose of study drug. Women who are not post-menopausal ≥ 52 weeks or surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation) are considered of childbearing potential. For women of childbearing potential (WOCBP), a serum pregnancy test (β-hCG) must be negative at Screening, and a urine pregnancy test must be negative prior to each dose of study drug.
  9. Breastfeeding: Patients must not be lactating or breastfeed during the study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued prior to the first dose of study drug.
  10. Contraception: If sexually active, WOCBP must agree to use contraception considered adequate and appropriate by the Investigator throughout the course of the study and for 30 days after she receives the last dose of study drug.
  11. Able and willing to adhere to all protocol requirements and study procedures throughout the study.
  12. Ability to comprehend and be informed of the nature of the study, as assessed by study clinic staff.

Exclusion Criteria:

  1. Patients with a history of other malignancies, except for adequately treated nonmelanoma skin cancer, curatively treated in-situ carcinoma of the cervix, in-situ carcinoma of the breast or other solid tumors with no evidence of recurrence for ≥ 5 years.
  2. Patients who have previously received a taxane within the 30 days prior to randomization.
  3. Patients who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, or radiotherapies Grade 1 or higher by CTCAE, with the exception of alopecia.
  4. Prior chemotherapy must be completed at least 30 days prior to randomization (42 days for mitomycin C or nitrosoureas). Prior immunotherapy, prior anti-tumor hormonal therapy, and prior radiotherapy must be completed at least 14 days prior to randomization. Radiotherapy is not allowed during the study. Administration of other chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not allowed.
  5. Patient had major surgery within 30 days prior to randomization, or patient has not recovered from prior major surgery.
  6. Sensory / Peripheral neuropathy of Grade 2 or higher by CTCAE at Screening.
  7. Patients with known brain metastases, with the exception of patients who have completed surgery and/or radiotherapy at least 30 days prior to randomization, have completed any steroids as treatment for the metastases at least 30 days prior to randomization, and who are currently asymptomatic.
  8. Known history or presence of any clinically significant disease or condition other than cancer unless determined as not clinically significant by the Investigator.
  9. History of difficulty with vascular access.
  10. Known history or presence of:

    1. Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
    2. Alcohol or drug abuse or dependence within one year prior to randomization
    3. Hypersensitivity or idiosyncratic reaction to paclitaxel, its excipients, and/or related substances, including, albumin and PEG.
  11. Patients may not participate in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or the use of investigational devices with therapeutic intent within 30 days prior to randomization and while enrolled in this study.
  12. Use of any CYP2C8 and CYP3A4 inhibitor (e.g., ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) or inducer (e.g., rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine) in the previous 14 days before randomization until the last PK sample is obtained in the study.
  13. Acute active infection requiring treatment within 14 days prior to randomization.
  14. Patients with any significant history of non-compliance or inability to reliably grant informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02064829

United States, Arkansas
Sorrento investigational site
Fayetteville, Arkansas, United States, 72703
United States, Tennessee
Sorrento investigational site
Chattanooga, Tennessee, United States, 37421
Sorrento investigational site
Memphis, Tennessee, United States, 38120
United States, Texas
Sorrento investigational site
Flower Mound, Texas, United States, 75028
Sorrento investigational site
Batumi, Georgia
Sorrento investigational site
Tbilisi, Georgia
Moldova, Republic of
Sorrento investigational site
Chisinau, Moldova, Republic of
Sorrento investigational site
Bucharest, Romania
Sorrento investigational site
Belgrade, Serbia
Sorrento investigational site
Kragujevac, Serbia
Sorrento investigational site
Sremska Kamenica, Serbia
Sorrento investigational site
Zrenjanin, Serbia
Sorrento investigational site
Singapore, Singapore, 169610
Sorrento investigational site
Cherkasy, Ukraine
Sorrento investigational site
Dnipropetrovsk, Ukraine
Sorrento investigational site
Kharkiv, Ukraine
Sorrento investigational site
Kyiv, Ukraine
Sorrento investigational site
Lviv, Ukraine
Sorrento investigational site
Sumy, Ukraine
Sorrento investigational site
Vinnytsya, Ukraine
Sponsors and Collaborators
Sorrento Therapeutics, Inc.
  More Information

Responsible Party: Sorrento Therapeutics, Inc. Identifier: NCT02064829     History of Changes
Other Study ID Numbers: STI-102
Study First Received: February 14, 2014
Last Updated: March 23, 2016

Keywords provided by Sorrento Therapeutics, Inc.:
Metastatic breast cancer
Locally recurrent breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017